News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VBL Therapeutics Discloses Data About VB-201 Novel Mechanism and Pre-Clinical Efficacy in Atherosclerosis


7/8/2013 10:12:52 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis. The manuscript reports that VB-201 can broadly inhibit monocyte chemotaxis, with up to 90% efficacy in vitro. Molecular analysis revealed that the effect of VB-201 was not restricted to a specific chemotactic ligand or receptor. In vivo, oral treatment with VB-201 reduced monocyte migration in a peritonitis model and inhibited atheroma development in ApoE-/-mice, without affecting cholesterol or triglyceride levels.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES